Trevi Therapeutics, Inc. (TRVI) saw its stock price plummet 5.39% during intraday trading on Wednesday, following the release of its first-quarter financial results.
The company reported a Q1 loss of $0.09 per diluted share, which was unchanged from the same period a year earlier. However, this result missed the FactSet analyst consensus estimate, which had expected a loss of $0.08 per share.
The earnings disappointment appears to be the primary driver behind the stock's sharp decline in the session.